tiprankstipranks
Advertisement
Advertisement
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
1M ago
Analyst Maintains Buy on ARS Pharmaceuticals as Neffy Access Prospects and Commercial Execution Improve
Premium
Ratings
Analyst Maintains Buy on ARS Pharmaceuticals as Neffy Access Prospects and Commercial Execution Improve
1M ago
ARS Pharmaceuticals price target raised to $30 from $12 at Cantor Fitzgerald
Premium
The Fly
ARS Pharmaceuticals price target raised to $30 from $12 at Cantor Fitzgerald
1M ago
Options Volatility and Implied Earnings Moves Today, May 15, 2026
PremiumMarket NewsOptions Volatility and Implied Earnings Moves Today, May 15, 2026
2M ago
ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion
Premium
Company Announcements
ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion
2M ago
ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)
Premium
The Fly
ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)
2M ago
Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction
PremiumCompany AnnouncementsArs Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction
3M ago
ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
Premium
The Fly
ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
4M ago
Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
Premium
TipRanks Newswire
Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100